This Radiopharmaceuticals market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The radiopharmaceuticals market size has grown steadily in recent years. It will grow from $6.46 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.
The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $10.59 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing geriatric population, increasing prevalence of cancer and cardiovascular diseases, high capital investments, and new product launches. Major trends in the forecast period include collaborating with other companies to boost revenues and improve product quality, investing in plant capacity expansions to cater to the increasing demand, investing in new technologies to meet the emerging demands, explore in silico modeling for a more rational and scientific approach, invest in AI to reduce R&D costs and save drug development time, invest in technologies catering to cardiology to boost revenues and accept disease-specific approaches for accurate and timely diagnosis of cancer.
The rising prevalence of cancer and cardiovascular diseases is expected to drive demand for the radiopharmaceuticals market. Radiopharmaceuticals are becoming a safe and effective therapeutic option compared to conventional medicines, offering advantages such as targeted therapy that benefits radiologists in treating these conditions. Cancer is recognized as the second leading cause of death globally, accounting for approximately 1 in 6 deaths. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a France-based specialized agency, reported that in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide. By 2040, these figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually.
The radiopharmaceuticals market is anticipated to experience significant growth, driven by the increasing demand for personalized medicine. Personalized medicine, also known as precision medicine, is an innovative approach to medical care that tailors medical decisions, treatments, interventions, and drug therapies to the unique characteristics of each patient. Integrating personalized medicine into radiopharmaceuticals enhances the precision and accuracy of imaging and therapy, enabling healthcare providers to deliver more targeted and effective care. For example, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34%, or 12 of them, classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing demand for personalized medicine is thus a driving force behind the growth of the radiopharmaceuticals market.
Several companies in the radiopharmaceuticals market are adopting strategic initiatives such as opening new manufacturing facilities and expanding plant capacity, gaining significant popularity. ITM Isotopen Technologien München AG (ITM), for instance, launched a new manufacturing facility in the Munich area to increase the production capacity of high-purity (n.c.a.) Lutetium-177 and no-carrier-added (n.c.a.) Lutetium-177-containing radiopharmaceuticals. This move aims to meet the high demand for quality medical isotopes for precision oncology worldwide.
Major players in the radiopharmaceuticals market are forming partnerships to enhance their market profitability. In June 2023, the University of Pittsburgh Medical Center partnered with PharmaLogic Holdings Corporation to produce new radiopharmaceuticals at a Pittsburgh facility. This collaboration enables patients and professionals in the UPMC vicinity to access innovative diagnostic and therapeutic drugs that are not currently available. The non-exclusive agreement outlines the conversion of experimental radiopharmaceuticals into therapeutically useful medications.
In January 2024, Eli Lilly, a US-based pharmaceutical company, completed its acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to enhance its capabilities in the emerging field of radioligand therapies, which aim to make significant advancements in cancer treatment. Point Biopharma specializes in radiopharmaceuticals, complementing Lilly's existing oncology portfolio and promising to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for various cancers.
Radiopharmaceuticals, also known as radioactive medications, are substances used for the diagnosis or treatment of diseases, including cancer, and contain a radioactive material. These medications are employed in various medical procedures to identify specific illnesses or detect medical issues. Patients may receive radiopharmaceuticals through different administration methods, such as injection, oral ingestion, or application into the eye or bladder.
Radiopharmaceuticals can be broadly categorized into diagnostic, therapeutic, and other types. The process of delivering radioactive atoms to targets associated with tumors is known as radiopharmaceutical therapy. These medications find applications in fields such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others. Hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and similar healthcare facilities commonly utilize radiopharmaceuticals for various medical purposes.
The radiopharmaceuticals market research report is one of a series of new reports that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the radiopharmaceuticals market include Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Řež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.
North America was the largest region in the global radiopharmaceuticals market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The radiopharmaceuticals market size has grown steadily in recent years. It will grow from $6.46 billion in 2024 to $6.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.
The radiopharmaceuticals market size is expected to see rapid growth in the next few years. It will grow to $10.59 billion in 2029 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing geriatric population, increasing prevalence of cancer and cardiovascular diseases, high capital investments, and new product launches. Major trends in the forecast period include collaborating with other companies to boost revenues and improve product quality, investing in plant capacity expansions to cater to the increasing demand, investing in new technologies to meet the emerging demands, explore in silico modeling for a more rational and scientific approach, invest in AI to reduce R&D costs and save drug development time, invest in technologies catering to cardiology to boost revenues and accept disease-specific approaches for accurate and timely diagnosis of cancer.
The rising prevalence of cancer and cardiovascular diseases is expected to drive demand for the radiopharmaceuticals market. Radiopharmaceuticals are becoming a safe and effective therapeutic option compared to conventional medicines, offering advantages such as targeted therapy that benefits radiologists in treating these conditions. Cancer is recognized as the second leading cause of death globally, accounting for approximately 1 in 6 deaths. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a France-based specialized agency, reported that in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred worldwide. By 2040, these figures are projected to rise to 29.9 million new cases and 15.3 million deaths annually.
The radiopharmaceuticals market is anticipated to experience significant growth, driven by the increasing demand for personalized medicine. Personalized medicine, also known as precision medicine, is an innovative approach to medical care that tailors medical decisions, treatments, interventions, and drug therapies to the unique characteristics of each patient. Integrating personalized medicine into radiopharmaceuticals enhances the precision and accuracy of imaging and therapy, enabling healthcare providers to deliver more targeted and effective care. For example, in 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34%, or 12 of them, classified as personalized medicines by the Personalized Medicine Coalition (PMC). The increasing demand for personalized medicine is thus a driving force behind the growth of the radiopharmaceuticals market.
Several companies in the radiopharmaceuticals market are adopting strategic initiatives such as opening new manufacturing facilities and expanding plant capacity, gaining significant popularity. ITM Isotopen Technologien München AG (ITM), for instance, launched a new manufacturing facility in the Munich area to increase the production capacity of high-purity (n.c.a.) Lutetium-177 and no-carrier-added (n.c.a.) Lutetium-177-containing radiopharmaceuticals. This move aims to meet the high demand for quality medical isotopes for precision oncology worldwide.
Major players in the radiopharmaceuticals market are forming partnerships to enhance their market profitability. In June 2023, the University of Pittsburgh Medical Center partnered with PharmaLogic Holdings Corporation to produce new radiopharmaceuticals at a Pittsburgh facility. This collaboration enables patients and professionals in the UPMC vicinity to access innovative diagnostic and therapeutic drugs that are not currently available. The non-exclusive agreement outlines the conversion of experimental radiopharmaceuticals into therapeutically useful medications.
In January 2024, Eli Lilly, a US-based pharmaceutical company, completed its acquisition of Point Biopharma for approximately $1.4 billion. This acquisition aligns with Lilly's strategy to enhance its capabilities in the emerging field of radioligand therapies, which aim to make significant advancements in cancer treatment. Point Biopharma specializes in radiopharmaceuticals, complementing Lilly's existing oncology portfolio and promising to improve patient outcomes. Point Biopharma is a US-based company focused on developing targeted radioligand therapies for various cancers.
Radiopharmaceuticals, also known as radioactive medications, are substances used for the diagnosis or treatment of diseases, including cancer, and contain a radioactive material. These medications are employed in various medical procedures to identify specific illnesses or detect medical issues. Patients may receive radiopharmaceuticals through different administration methods, such as injection, oral ingestion, or application into the eye or bladder.
Radiopharmaceuticals can be broadly categorized into diagnostic, therapeutic, and other types. The process of delivering radioactive atoms to targets associated with tumors is known as radiopharmaceutical therapy. These medications find applications in fields such as oncology, cardiology, gastroenterology, neuroendocrinology, neurology, nephrology, and others. Hospitals, ambulatory surgical centers, diagnostic centers, cancer research institutes, and similar healthcare facilities commonly utilize radiopharmaceuticals for various medical purposes.
The radiopharmaceuticals market research report is one of a series of new reports that provides radiopharmaceuticals market statistics, including radiopharmaceuticals industry global market size, regional shares, competitors with a radiopharmaceuticals market share, detailed radiopharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the radiopharmaceuticals industry. This radiopharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
Major companies operating in the radiopharmaceuticals market include Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Řež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.
North America was the largest region in the global radiopharmaceuticals market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiopharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The radiopharmaceuticals market consists of sales of technetium disofenin, technetium lidofenin, and technetium mebrofenin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Radiopharmaceuticals Market Characteristics3. Radiopharmaceuticals Market Trends and Strategies4. Radiopharmaceuticals Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Radiopharmaceuticals Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Radiopharmaceuticals Market34. Recent Developments in the Radiopharmaceuticals Market
5. Global Radiopharmaceuticals Growth Analysis and Strategic Analysis Framework
6. Radiopharmaceuticals Market Segmentation
7. Radiopharmaceuticals Market Regional and Country Analysis
8. Asia-Pacific Radiopharmaceuticals Market
9. China Radiopharmaceuticals Market
10. India Radiopharmaceuticals Market
11. Japan Radiopharmaceuticals Market
12. Australia Radiopharmaceuticals Market
13. Indonesia Radiopharmaceuticals Market
14. South Korea Radiopharmaceuticals Market
15. Western Europe Radiopharmaceuticals Market
16. UK Radiopharmaceuticals Market
17. Germany Radiopharmaceuticals Market
18. France Radiopharmaceuticals Market
19. Italy Radiopharmaceuticals Market
20. Spain Radiopharmaceuticals Market
21. Eastern Europe Radiopharmaceuticals Market
22. Russia Radiopharmaceuticals Market
23. North America Radiopharmaceuticals Market
24. USA Radiopharmaceuticals Market
25. Canada Radiopharmaceuticals Market
26. South America Radiopharmaceuticals Market
27. Brazil Radiopharmaceuticals Market
28. Middle East Radiopharmaceuticals Market
29. Africa Radiopharmaceuticals Market
30. Radiopharmaceuticals Market Competitive Landscape and Company Profiles
31. Radiopharmaceuticals Market Other Major and Innovative Companies
35. Radiopharmaceuticals Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Radiopharmaceuticals Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on radiopharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for radiopharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The radiopharmaceuticals market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Diagnostic, Therapeutic2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
3) By End User: Hospitals and Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
Subsegments:
1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals; Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals2) By Therapeutic: Alpha Emitters; Beta Emitters; Brachytherapy
Key Companies Mentioned: Cardinal Health; Curium Pharma; Siemens Healthineers AG; Novartis AG; General Electric Company (GE)
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Radiopharmaceuticals market report include:- Cardinal Health
- Curium Pharma
- Siemens Healthineers AG
- Novartis AG
- General Electric Company (GE)
- IBA Group
- Bayer AG
- Lantheus Medical Imaging Inc.
- Bracco Imaging S.p.A.
- Eckert & Ziegler
- Nihon Medi-Physics Co. Ltd.
- Fujifilm Corporation
- ANSTO
- Yantai Dongcheng Pharmaceutical Group Co. Ltd.
- Bracco Imaging SpA.
- Canon Inc.
- China Isotope & Radiation Corporation (CIRC)
- Alliance Medical
- Advanced Accelerator Applications
- JSC Isotope
- Pharm-Sintez
- Synektik SA
- Polatom
- RadioMedic sro
- ÚJV Řež
- Actinium Pharmaceuticals Inc.
- Alseres Pharmaceuticals Inc.
- Avid Radiopharmaceuticals
- Fusion Pharmaceuticals
- Peregrine Pharmaceuticals Inc.
- PETNET Solutions Inc.
- Positron Corporation
- Triad Isotopes Inc.
- Telix Pharmaceuticals
- Rosatom
- Alliance Medical Group
- Hologic Inc.
- Segami Corporation
- Eczacýbaþý-Monrol Nuclear Products
- NTP Radioisotopes.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 6.77 Billion |
| Forecasted Market Value ( USD | $ 10.59 Billion |
| Compound Annual Growth Rate | 11.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 41 |
